Revolution Medicines (RVMD) Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RVMD shares.
View RVMD analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 12 month price objectives for Revolution Medicines' stock. Their RVMD share price forecasts range from $23.00 to $38.00. On average, they expect the company's share price to reach $33.00 in the next year. This suggests a possible upside of 30.4% from the stock's current price.
View analysts price targets for RVMD or view top-rated stocks among Wall Street analysts.

Revolution Medicines' stock was trading at $23.82 at the start of the year. Since then, RVMD shares have increased by 6.2% and is now trading at $25.30.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our RVMD earnings forecast.

Revolution Medicines, Inc. (NASDAQ:RVMD) posted its quarterly earnings data on Monday, May, 8th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.12. The company had revenue of $7.01 million for the quarter, compared to the consensus estimate of $2.94 million. Revolution Medicines had a negative trailing twelve-month return on equity of 36.79% and a negative net margin of 744.36%. The company's quarterly revenue was down 7.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.78) earnings per share.

ETFs with the largest weight of Revolution Medicines (NASDAQ:RVMD) stock in their portfolio include SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), BlackRock Future Health ETF (BMED), JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL).

(RVMD) raised $150 million in an IPO on Thursday, February 13th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.

Revolution Medicines trades on the NASDAQ under the ticker symbol "RVMD."

Revolution Medicines' stock is owned by a number of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (9.81%), BlackRock Inc. (7.02%), EcoR1 Capital LLC (5.03%), Price T Rowe Associates Inc. MD (4.74%), BVF Inc. IL (4.66%) and Nextech Invest Ltd. (4.55%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Elizabeth M Anderson, Jack Anders, Jeanna Steele, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Thilo Schroeder, Vincent A Miller and Xiaolin Wang.
View institutional ownership trends.

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RVMD stock can currently be purchased for approximately $25.30.

Revolution Medicines (NASDAQ:RVMD) has a market capitalization of $2.69 billion and generates $35.38 million in revenue each year. The company earns $-248,710,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.

The company employs 188 workers across the globe.

Revolution Medicines' mailing address is 700 Saginaw Drive, Redwood City CA, 94063. The official website for the company is www.revmed.com. The company can be reached via phone at 650-481-6801 or via email at ir@revmed.com.